EYE · XBRL financial data

National Vision Holdings financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (EYE's year ends in early January)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 30, 2023	Q1 FY24Mar 30, 2024	Q2 FY24Jun 29, 2024	Q3 FY24Sep 28, 2024	Q4 FY24Dec 28, 2024	Q1 FY25Mar 29, 2025	Q2 FY25Jun 28, 2025	Q3 FY25Sep 27, 2025	Q4 FY25Jan 3, 2026	Q1 FY26Apr 4, 2026	Q2 FY26Jul 4, 2026
Revenue from contracts with customers	532	421	543	452	452	437	510	486	487	503*	544	499
Selling, general and administrative	250	248*	245	231	234	233*	256	247	252	261*	256	243
Total operating expenses	355	273*	269	258	270	278*	279	270	275	286*	280	269
Other operating income (expense)	0	0*	0	0	0	0*	0	0	0	0*	0	0
Operating income (loss)	(75)	(12)	24	1	(9)	(26)	26	16	10	7*	45	21
Income tax expense (benefit)	(5)	(2)*	8	(2)	(4)	(1)*	7	4	2	(1)*	11	6
Net income (loss)	(74)	(16)	12	(3)	(8)	(29)	14	9	3	3*	31	12
Earnings per share, basic USD per share	(0.94)	(0.20)	0.15	(0.04)	(0.11)	(0.36)	0.18	0.11	0.04	0.04*	0.39	0.16
Earnings per share, diluted USD per share	(0.94)	(0.20)	0.15	(0.04)	(0.11)	(0.36)	0.18	0.11	0.04	0.04*	0.38	0.15
Weighted average shares, basic millions of shares	78	78	78	79	79	79	79	79	79	79*	80	80
Weighted average shares, diluted millions of shares	78	78	79	79	79	79	79	80	81	82*	81	81

Fiscal quarters (EYE's year ends in early January)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 30, 2023	Q1 FY24Mar 30, 2024	Q2 FY24Jun 29, 2024	Q3 FY24Sep 28, 2024	Q4 FY24Dec 28, 2024	Q1 FY25Mar 29, 2025	Q2 FY25Jun 28, 2025	Q3 FY25Sep 27, 2025	Q4 FY25Jan 3, 2026	Q1 FY26Apr 4, 2026	Q2 FY26Jul 4, 2026
Cash and cash equivalents	266	150	150	180	81	74	80	48	56	39	68	36
Accounts receivable	77	87	74	61	47	50	53	46	46	57	44	35
Inventory	121	120	119	91	88	94	89	90	88	89	108	123
Prepaid and other current assets	37	40	36	33	28	32	32	34	30	40	41	33
Total current assets	500	397	379	364	244	250	254	218	220	226	261	227
Right-of-use asset	403	407	411	414	420	409	403	392	387	395	397	404
Goodwill	718	718	718	718	718	698	698	698	701	701	701	701
Total assets	2,266	2,173	2,155	2,146	2,020	2,008	2,010	1,968	1,958	1,984	2,020	1,983
Accounts payable	63	68	61	50	40	54	37	65	74	79	87	77
Accrued liabilities	113	123	108	110	94	109	115	127	112	110	107	91
Current portion of long-term debt	8	8	8	310	98	98	98	13	13	13	13	13
Total current liabilities	374	398	375	663	426	468	468	418	417	412	418	383
Long-term debt	538	438	436	132	242	239	236	248	230	223	220	217
Lease liability, non-current	375	377	380	383	389	366	358	345	338	358	359	365
Retained earnings	271	255	266	263	255	226	240	249	252	256	287	299
Total stockholders' equity	840	829	841	843	840	816	836	851	859	870	898	897
Total liabilities and equity	2,266	2,173	2,155	2,146	2,020	2,008	2,010	1,968	1,958	1,984	2,020	1,983
Common shares outstanding (cover page) millions of shares	78	78	79	79	79	79	79	79	79	79	80	79

Fiscal quarters (EYE's year ends in early January)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 30, 2023	Q1 FY24Mar 30, 2024	Q2 FY24Jun 29, 2024	Q3 FY24Sep 28, 2024	Q4 FY24Dec 28, 2024	Q1 FY25Mar 29, 2025	Q2 FY25Jun 28, 2025	Q3 FY25Sep 27, 2025	Q4 FY25Jan 3, 2026	Q1 FY26Apr 4, 2026	Q2 FY26Jul 4, 2026
Net income (loss)	(74)	(16)	12	(3)	(8)	(29)	14	9	3	3*	31	12
Stock-based compensation	5*	5*	2	5*	5*	5*	7	5*	6*	6*	7	6*
Net cash from operating activities	41*	20*	24	51*	28*	30*	32	54*	47*	13*	62	8*
Purchases of property and equipment	28*	33*	20	20*	24*	32*	20	12*	16*	24*	18	22*
Net cash from investing activities	(28)*	(33)*	(18)	(20)*	(24)*	(34)*	(20)	(13)*	(19)*	(24)*	(18)	(16)*
Share repurchases	0*	1*	3	0*	0*	0*	2	0*	1*	1*	11	20*
Proceeds from long-term debt	—	0*	—	—	115*	0*	—	—	(15)*	25*	—	—
Repayments of long-term debt	2*	101*	2	2*	215*	3*	3	88*	3*	32*	3	13*
Net cash from financing activities	(2)*	(103)*	(5)	(2)*	(102)*	(4)*	(5)	(73)*	(20)*	(6)*	(14)	(24)*
Net change in cash	11*	(116)*	1	29*	(98)*	(7)*	7	(32)*	8*	(17)*	29	(32)*

SIC 3851 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3851 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
National Vision Holdings	36	499	8.1*	79.1M	Q2 FY26 10-QJul 4, 2026
Staar Surgical	149	94	20*	50.1M	Q2 FY26 10-QJul 3, 2026
Warby Parker	293	236	30*	not reported	Q2 FY26 10-QJun 30, 2026
Bausch & Lomb	513	1,375	233*	357.5M	Q3 FY26 10-QSep 30, 2026
RxSight	67	25	45*	41.9M	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.